Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

Compugen Announces Development of NexGen Infrastructure

Published: Tuesday, July 03, 2012
Last Updated: Tuesday, July 03, 2012
Bookmark and Share
New platform significantly enhances drug and target discovery potential of Compugen's LEADS and MED platforms.

Compugen Ltd. has announced the development of "NexGen," a new platform designed to significantly enhance Compugen's overall infrastructure for predictive drug and drug target discovery. NexGen is designed to analyze Next Generation Sequencing data which is now beginning to be generated worldwide through RNA-Seq methodology. RNA-Seq is a new and powerful ultra-high throughput approach to provide raw data for transcriptome analysis and expression profiling. Although this new approach provides a massive amount of data in the form of very short partial transcript sequences, it also creates an extremely challenging environment for obtaining meaningful and accurate information.

Compugen's NexGen Platform, which incorporates advanced algorithms and other proprietary tools, is designed to efficiently and accurately integrate and analyze this vast amount of short sequence data. The integration of this capability with Compugen's discovery infrastructure, mainly its predictive transcriptome and proteome, is expected to provide the Company with both enhanced identification of novel genes and splice variants, and a broader view of the expression levels of RNA transcripts, facilitating new associations to pathological or healthy conditions. These new integrated capabilities should provide Compugen with further substantial advantages in predictive discovery of potential drugs and drug targets, and also in the discovery of potential diagnostic product candidates.

The proprietary insights obtained by Compugen's decade-long pioneering research focused on predictive transcriptome and expression analysis, which resulted in the Company's LEADS and MED platforms, were fundamental in overcoming the technological challenges in building the NexGen platform. In turn, by enabling the integration and analysis of this enormous quantity of additional data, the NexGen platform adds significant advantages to LEADS and MED, the infrastructure platforms that support all of Compugen's drug and target product candidate discovery platforms. Similar to the LEADS and MED platforms, NexGen is broadly applicable across essentially all therapeutic and diagnostic areas, but its primary use will be in support of the Company's focus areas of novel therapeutic proteins and monoclonal antibodies for oncology and immunology, highly complex therapeutic areas with significant unmet medical needs.

Dr. Zurit Levine, Compugen's VP of Research and Discovery, stated, "New RNA-seq high-throughput sequencing techniques are beginning to generate vast quantities of data that provide a potentially invaluable, but difficult to utilize, resource for use in the discovery of drugs and diagnostics. This is particularly true with respect to complex diseases such as cancer and immune-related pathologies. Therefore, our successful development of the NexGen platform, built on, extending and enhancing our existing predictive capabilities, represents an important addition to our infrastructure for internal discovery as well as for discovery collaborations with others."

Dr. Anat Cohen-Dayag, President and CEO of Compugen, added, "NexGen is an excellent example of how Compugen benefits on an ongoing basis from our decade-long and continuing pioneering efforts to create deeper scientific understandings, algorithms, and approaches for predictive modeling of key biological phenomena at the molecular level. Built from the "bottom up," our unique predictive discovery infrastructure can readily integrate new technologies such as RNA-seq, as part of the process by which this infrastructure is continuously enhanced and expanded."

Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,100+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Compugen Appoints Martin Gerstel CEO Effective January 2009
Mr. Gerstel, who has served as chairman of Compugen since 1997, will succeed current president and chief executive officer Mr. Alex Kotzer.
Friday, November 14, 2008
Scientific News
Integrated Omics Analysis
Studying multi-omics promises to give a more holistic picture of the organism and its place in its ecosystem, however despite the complexities involved those within the field are optimistic.
Salford Lung Study - The First Real World Clinical Trial
In this podcast, we learn about the Salford Lung Study and its potential to revolutionize the way we assess new drugs and treatments around the world.
Supercomputers Could Improve Cancer Diagnostics
Researchers push the boundaries of cancer research through high-performance computing to map the human immunone.
Systems Medicine – The Future Approach to Diseases
Review give insight into the future of understanding the body and its mechanisms through systems medicine.
Genetic Signature Linked to Cancer Prognosis Identified
The results of the analysis of 8,161 tissue samples could in the future help clinicians decide how best to treat a patient as well as aid the development of new targeted treatments.
Mapping the Human Immune System
Researchers try to harness supercomputers to create the first map of the human immune system.
Microsatellites Linked to Cancer
DNA repeat stretches, called microsatellites, play a greater role in cancer progression and survival that previously thought.
Universal Flu Vaccine Designed by Scientists
An international team of scientists have designed a new generation of universal flu vaccines to protect against future global pandemics that could kill millions.
Faecal Bacteria Linked to Body Fat
Researchers at King’s College London have found a new link between the diversity of bacteria in human poo – known as the human faecal microbiome - and levels of abdominal body fat.
NCI Collaborates with Multiple Myeloma Research Foundation
NCI collaborates with MMRF to incorporate genomic and clinical data into NCI Genomic Data Commons database.
Scroll Up
Scroll Down

SELECTBIO Market Reports
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,100+ scientific videos